Chronic heart failure (CHF) is the final stage in the development of cardiovascular diseases. Its development is directly associated with the age of patients. Patients with CHF are recommended to prescribe drugs that stabilize the clinical condition and improve the long-term prognosis. However, elderly patients are underrepresented in randomized controlled trials of CHF, which limits the possibility of generalizing the results of studies in real clinical practice for elderly patients with CHF. Older age and the presence of frailty are factors that limit the prescription of recommended drugs and lead to lower adherence to optimal drug therapy in elderly patients. The review analyzes the results of original studies on the problems of the current state of optimal drug therapy for patients with CHF, including in older patient populations, as well as some interventions that may help improve adherence to evidence-based recommendations in older age groups.

Keywords: sodium-glucose cotransporter type 2 inhibitors, sarcopenia, elderly patients, chronic heart failure